title: Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer.
abstract: BACKGROUND
  The survival of patients with stage IV gastric cancer is poor due to frequent peritoneal failure. The aim of this study was to investigate the impact of early postoperative intraperitoneal chemotherapy (EPIC) after cytoreductive surgery on the long-term survival of these patients, as determined by residual disease status.
  
  
  METHODS
  A total of 154 patients with stage IV gastric cancer were enrolled in our study. All patients underwent potentially curative or palliative resections. After surgery, the residual disease states of the patients were recorded. All patients received EPIC.
  
  
  RESULTS
  Of all 154 patients, R0 resection was achieved in 37, R1 in 56, and R2 in 61. All patients received a mean of 4.3 EPIC perfusions. After a mean followup period of 29 months, 14 patients remained alive. The median survival of all 154 patients was 11.4 months. Survival times were analyzed according to the type of residual tumor; the median survival time was 25.5 months in the R0 group, 15.6 months in the R1 group, and 7.2 months in the R2 group (p < .001). Upon multivariate analysis, the residual tumor states and the cycle of EPIC perfusion were found to be independent prognostic predictors (p < .001 and p = .018, respectively).
  
  
  CONCLUSIONS
  The residual tumor status is the most important predictor for the survival of very advanced gastric cancer patients who received cytoreductive surgery and EPIC. Therefore, complete cytoreductive surgery yielding R0 resection is mandatory for achieving the beneficial effects of EPIC.
authors.affiliation: Department of Surgery, Yonsei University College of Medicine, Seoul, 120-752, Korea.
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Cheong
authors.forename: Jia Yun
authors.initials: JY
authors.lastname: Shen
authors.forename: Chang Soo
authors.initials: CS
authors.lastname: Song
authors.forename: Woo Jin
authors.initials: WJ
authors.lastname: Hyung
authors.forename: Jian Guo
authors.initials: JG
authors.lastname: Shen
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Choi
authors.forename: Sung Hoon
authors.initials: SH
authors.lastname: Noh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate